logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5829.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Export All Citations
Copyright © Médecins Sans Frontières
v2.1.5829.produseast1
Showing 1 - 20 of 85 Items
Showing 1 - 20 of 85 Items
Citations
  • Download citations in various formats (CSV, BibTeX, EndNote) for use in reference managers and bibliographies.
  • Current Page (20)
  • CSV
  • BibTeX
  • EndNote
  • All Results (85)
  • CSV
  • BibTeX
  • EndNote
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Letter

Monkeypox virus–HIV co-infections in Sierra Leone

Hoffmann Dahl E, Jiba DF, Casas EC, Jonckheere S, Dama A,  et al.
2025-09-12 • Lancet Infectious Diseases
2025-09-12 • Lancet Infectious Diseases
Journal Article
|
Review
Journal Article
|
Letter
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Review

Embedding treatment in stronger care systems

Rojek A, Fieggen J, Paterson A, Byakika-Kibwika P, Camara M,  et al.
2024-12-12 • Lancet Infectious Diseases
Journal Article
|
Review
Journal Article
|
Research
Journal Article
|
Case Report/Series
Journal Article
|
Commentary

Accumulating evidence on the long-term immunogenicity of fractional dosing for yellow fever vaccines

Juan-Giner A, Warimwe GM
2024-06-01 • Lancet Infectious Diseases
2024-06-01 • Lancet Infectious Diseases
Journal Article
|
Letter
Journal Article
|
Research
Journal Article
|
Review
Journal Article
|
Commentary

Revisiting the minimum incubation period of Zaire ebolavirus

Journal Article
|
Research
Journal Article
|
Commentary
Journal Article
|
Commentary
Journal Article
|
Letter
Journal Article
|
Research
Journal Article
|
Research

Management of individuals exposed to multidrug-resistant or rifampicin-resistant tuberculosis

Seddon JA, Achar J, Malik AA, Hughes J, Burzynski J,  et al.
2025-06-06 • Lancet Infectious Diseases
2025-06-06 • Lancet Infectious Diseases

DR Congo's conflict and cholera: a call for ring vaccination

Al-Rabeeah AA, Ebrahim SH, Mwamba D, Ditekemena J, Christou C,  et al.
2025-04-04 • Lancet Infectious Diseases
2025-04-04 • Lancet Infectious Diseases

The effectiveness of two doses of recombinant hepatitis E vaccine in response to an outbreak in Bentiu, South Sudan: a case–control and bias indicator study

Nesbitt RC, Kinya Asilaza V, Alvarez C, Gitahi P, Nkemenang P,  et al.
2025-01-08 • Lancet Infectious Diseases
2025-01-08 • Lancet Infectious Diseases

BACKGROUND

Hepatitis E virus (HEV) is a leading cause of acute viral hepatitis, particularly in Asia and Africa, where HEV genotypes 1 and 2 are prevalen...

Effect of mass campaigns with full and fractional doses of pneumococcal conjugate vaccine (Pneumosil) on the reduction of nasopharyngeal pneumococcal carriage in Niger: a three-arm, open-label, cluster-randomised trial

Coldiron ME, Soumana I, Baudin E, Langendorf C, Mamiafo Tchoula C,  et al.
2025-01-08 • Lancet Infectious Diseases
2025-01-08 • Lancet Infectious Diseases

BACKGROUND

In settings with low pneumococcal conjugate vaccine (PCV) coverage, multi-age cohort mass campaigns could increase population immunity, and fractiona...

2024-12-12 • Lancet Infectious Diseases

Ebola disease: Bridging scientific discoveries and clinical application

Rojek A, Fieggen J, Apiyo P, Caluwaerts S, Fowler RA,  et al.
2024-12-01 • Lancet Infectious Diseases
2024-12-01 • Lancet Infectious Diseases

The west Africa Ebola disease epidemic (2014-16) marked a historic change of course for patient care during emerging infectious disease outbreaks. The epidemic response was a failure ...

Field evaluation of validity and feasibility of Pan-Lassa rapid diagnostic test for Lassa fever in Abakaliki, Nigeria: a prospective diagnostic accuracy study

Elsinga J, Sunyoto T, di Stefano L, Giorgetti PF, Kyi HA,  et al.
2024-09-01 • Lancet Infectious Diseases
2024-09-01 • Lancet Infectious Diseases

BACKGROUND 

Lassa fever is a viral haemorrhagic fever with few options for diagnosis and treatment; it...

Effectiveness of rVSV-ZEBOV vaccination during the 2018–20 Ebola virus disease epidemic in the Democratic Republic of the Congo: a retrospective test-negative study

Meakin S, Nsio J, Camacho A, Kitenge R, Coulborn RM,  et al.
2024-08-01 • Lancet Infectious Diseases
2024-08-01 • Lancet Infectious Diseases

BACKRGOUND

The rec...

Reporting of deaths during cholera outbreaks: case fatality ratio and community deaths

Finger F, Heitzinger K, Berendes D, Ciglenecki I, Dominguez M,  et al.
2024-04-30 • Lancet Infectious Diseases
2024-04-30 • Lancet Infectious Diseases

Case fatality risk among individuals vaccinated with rVSVΔG-ZEBOV-GP: a retrospective cohort analysis of patients with confirmed Ebola virus disease in the Democratic Republic of the Congo

Coulborn RM, Bastard M, Peyraud N, Gignoux EM, Luquero FJ,  et al.
2024-02-01 • Lancet Infectious Diseases
2024-02-01 • Lancet Infectious Diseases
BACKGROUND
The rVSVΔG-ZEBOV-GP vaccine constitutes a valuable tool to control Ebola virus disease outbreaks. This retrospective cohort study aimed to assess the protective effect of ...

The status of combination therapy for visceral leishmaniasis: an updated review

van Griensven J, Dorlo TPC, Diro EGJ, Costa CH, Burza S
2024-01-01 • Lancet Infectious Diseases
2024-01-01 • Lancet Infectious Diseases
For the past 15 years, trials of combination therapy options for visceral leishmaniasis have been conducted with the aim of identifying effective, and safe treatment regimens that were s...
Kofman AD, Haberling DL, Mbuyi G, Martel LD, Whitesell AN,  et al.
2023-08-18 • Lancet Infectious Diseases
2023-08-18 • Lancet Infectious Diseases

Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial

Juan-Giner A, Namulwana ML, Kimathi D, Grantz KH, Fall G,  et al.
2023-04-28 • Lancet Infectious Diseases
2023-04-28 • Lancet Infectious Diseases
BACKGROUND
Current supply shortages constrain yellow fever vaccination activities, particularly outbreak response. Although fractional doses of all WHO-prequalified yellow fever vacc...

Strengthening the maternal and child health responses to Ebola outbreaks in Uganda

Chowdhury M, Ouma J, Nakabembe E, Mwanga-Amumpaire J, Kirenga B,  et al.
2023-04-24 • Lancet Infectious Diseases
2023-04-24 • Lancet Infectious Diseases

Moving towards malaria elimination with safer treatment for children with G6PD deficiency

Boum Y II, Moukoko CEE, Parikh S
2023-04-01 • Lancet Infectious Diseases
2023-04-01 • Lancet Infectious Diseases

On the importance and challenges of global access to proven life-saving treatments for Ebolavirus – Authors' reply

Torreele E, Boum Y, Adjaho I, Alé FGB, Issoufou SH,  et al.
2023-04-01 • Lancet Infectious Diseases
2023-04-01 • Lancet Infectious Diseases

Effect of systematic tuberculosis detection on mortality in young children with severe pneumonia in countries with high incidence of tuberculosis: a stepped-wedge cluster-randomised trial

Marcy O, Wobudeya E, Font H, Vessière A, Chabala C,  et al.
2023-03-01 • Lancet Infectious Diseases
2023-03-01 • Lancet Infectious Diseases
BACKGROUND
Tuberculosis diagnosis might be delayed or missed in children with severe pneumonia because this diagnosis is usually only considered in cases of prolonged symptoms or ant...

Hepatitis C seroprevalence and HIV co-infection in sub-Saharan Africa: a systematic review and meta-analysis

Rao VB, Johari N, du Cros PAK, Messina J, Ford NP,  et al.
2015-05-05 • Lancet Infectious Diseases
2015-05-05 • Lancet Infectious Diseases
An estimated 150 million people worldwide are infected with hepatitis C virus (HCV). HIV co-infection accelerates the progression of HCV and represents a major public health challenge. W...